Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study

• DOI: 10.3389/fonc.2022.839915
• Publication Date: 2022-03-03T05:13:01Z
• Authors: Alessandra Iurlo; Daniele Cattaneo; Silvia Artuso; Dario Consonni; Elisabetta Abruzzese; Gianni Binotto; Monica Bocchia; Massimiliano Boni...; Fausto Castagnetti; Sara Galimberti; Antonella Gozzini; Miriam Iezza; Roberto Latagliata; Luigiana Luciano; Alessandro Maggi; Maria Cristina Mi...; Patrizia Pregno; Giovanna Rege-Cam...; Sabina Russo; Anna Rita Scortec...; Agostino Tafuri; Mario Tiribelli; Carmen Fava; Gianantonio Rosti; Robin Foa; Massimo Breccia; Giuseppe Saglio
• Keywords: Hematology

Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction often used real-life practice to reduce adverse events, although its impact on TFR still matter of debate. This study aimed explore the attitude Italian hematologists towards prescribing at reduced doses TFR. In September 2020, questionnaire was sent 54 hematology centers Italy participating Campus network. For each patient, data main disease characteristics were collected. Most involved (64.4%) believed that low-dose should not influence Indeed, this approach offered 194 patients. At time TFR, all but 3 patients had already achieved DMR, with median duration 61.0 months. After follow-up 29.2 months, 138 (71.1%) Interestingly, outcome impaired any variables examined, including sex, risk scores, BCR-ABL1 transcript types, previous interferon, type number before treatment cessation, degree DMR or therapy. On contrary, significantly better after due AEs; furthermore, longer showed trend prolonged survey indicates TKI an important reality. While one third some uncertainties feasibility using outside clinical trials, been safe option even treated setting. It be noted only 28.9% our cases molecular recurrence, less than reported during standard treatment. Consequently, TKIs.